Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

News releases from Roivant Sciences

Roivant Sciences to Present at 39th Annual J.P. Morgan Healthcare Conference
Recent milestones include first two FDA approvals at Vants launched by Roivant, positive clinical data at Dermavant, Aruvant, and Immunovant, and multiple computationally-designed protein degraders... 
From PR Newswire
Roivant Unveils Targeted Protein Degradation Platform
- First therapeutic candidate on track to enter clinical studies in 2021 
From PR Newswire
Roivant Provides Updates for Pivotal BREATHE Clinical Trial Evaluating Gimsilumab in COVID-19 Patients for the Prevention and Treatment of Acute Respiratory Distress Syndrome
-- Independent Data Monitoring Committee unanimously recommends trial continuation after pre-specified safety assessment 
From PR Newswire
Roivant Doses First Patient in Pivotal BREATHE Clinical Trial Evaluating Gimsilumab in COVID-19 Patients for the Prevention and Treatment of Acute Respiratory Distress Syndrome
- BREATHE is an adaptive, randomized, double-blind, placebo-controlled trial expected to enroll up to 270 patients, with a planned interim analysis 
From PR Newswire
Roivant Announces Development of Anti-GM-CSF Monoclonal Antibody to Prevent and Treat Acute Respiratory Distress Syndrome (ARDS) in Patients with COVID-19
- Gimsilumab is a monoclonal antibody that targets GM-CSF, a pro-inflammatory cytokine found to be up-regulated in COVID-19 patients 
From PR Newswire
Roivant Launches Lokavant to Provide Real-Time and Anticipatory Clinical Trial Monitoring
- Lokavant has entered into multi-year enterprise license agreement with Parexel 
From PR Newswire
Roivant Sciences to Present at the 38th Annual J.P. Morgan Healthcare Conference
Roivant Sciences today announced that Vivek Ramaswamy, Founder and Chief Executive Officer of Roivant, will present an overview of recent developments and future directions for the business at the 38th... 
From PR Newswire
Roivant Provides Corporate Updates in Advance of Second Annual Pipeline Day
Roivant Sciences today announced a series of corporate updates across the Roivant family of companies in advance of its second annual Pipeline Day tomorrow afternoon in New York City. 
From PR Newswire
Roivant Statement on Positive Phase 3 Results from Myovant's LIBERTY 1 Study in Uterine Fibroids
- Second annual Roivant Pipeline Day on June 6th to feature additional clinical data from across Roivant family of companies 
From PR Newswire
Roivant and Sinovant Launch Cytovant Sciences in Partnership with Medigene to Develop Cellular Therapies in Asia
- Cytovant licenses East Asian rights for a research-stage T-cell receptor (TCR) against tumor antigen NY-ESO-1 as well as rights for Medigene's dendritic cell (DC) vaccine for the treatment of... 
From PR Newswire
Roivant Statement on Topline Results from EMPOWUR Phase 3 Study in Overactive Bladder
- Vibegron met both co-primary endpoints and all seven key secondary endpoints 
From PR Newswire
Roivant Announces Corporate Updates and Webcast of Presentation at 37th Annual J.P. Morgan Healthcare Conference
From PR Newswire
Roivant Sciences to Present at the 37th Annual J.P. Morgan Healthcare Conference
- In addition to Roivant, four Vants will be presenting at JPM this year 
Tickers AXON MYOV UROV
From PR Newswire
Roivant Sciences and Daiichi Sankyo Enter into Broad Pipeline Partnership
Roivant Sciences today announced that it has entered into a collaboration with Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) to facilitate the out-licensing of investigational medicines.... 
Tickers AXON
From PR Newswire
Roivant Launches Aruvant Sciences and Roivant Foundation in Partnership with Cincinnati Children's Hospital Medical Center
- Aruvant's pipeline anchored by RVT-1801, an investigational gene therapy for sickle cell disease and ?-thalassemia 
From PR Newswire
Roivant Sciences and iNtRON Bio Sign Licensing Deal for Novel Anti-Superbugs Biologic SAL200
- Roivant plans to initiate Phase 2 clinical trial in 2019 
From PR Newswire
Roivant Sciences Announces $200 Million Investment Round
Roivant Sciences today announced a $200 million equity financing. New investors include NovaQuest Capital Management, RTW Investments, and other large institutional asset managers. These new investors... 
From PR Newswire
Roivant Launches Respivant Sciences to Develop Innovative Therapeutics for Respiratory Diseases
- Respivant to be led by Bill Gerhart, former CEO of Patara Pharma and Elevation Pharmaceuticals 
Tickers AXON
From PR Newswire
Roivant Adds Investigational Therapeutic for the Treatment of Chronic Cough in Patients with Idiopathic Pulmonary Fibrosis to Pipeline
- Statistically significant reduction in cough frequency observed among IPF patients after 14 days of treatment in completed Phase 2a trial 
From PR Newswire
Roivant Sciences Provides Corporate Update
- Dr. Frank Torti, former partner at NEA, appointed Vant Investment Chair 
From PR Newswire
Roivant Sciences Provides Corporate Updates in Advance of First Annual Pipeline Day
Roivant Sciences announced a series of corporate updates across the Roivant family of companies in advance of its first annual Pipeline Day this afternoon in New York City. 
From PR Newswire
Roivant Announces Creation of Roivant Pharma and Roivant Health and Launch of Altavant
- Roivant to increase focus on incubating and launching new Vants, including new companies focused on earlier-stage and potentially transformative scientific platforms 
From PR Newswire
Roivant to Host First Annual Pipeline Day
-- Event to highlight recent developments and future directions for Roivant 
From PR Newswire
Roivant Expands Senior Leadership with Key Hires
- Dr. Sam Azoulay, former SVP and Chief Medical Officer at Pfizer Essential Health, joins as Chief Medical Officer 
From PR Newswire
Roivant Sciences Enters into Development Partnership with AstraZeneca
Roivant Sciences today announced that it has entered into a development partnership with AstraZeneca for a deprioritized investigational drug in an undisclosed indication. The drug will be developed by... 
From PR Newswire
Roivant Sciences Statement on MINDSET Results
Today our subsidiary Axovant announced topline results from its Phase 3 MINDSET trial of intepirdine in mild-to-moderate Alzheimer's disease. Unfortunately, intepirdine did not achieve a statistically... 
From PR Newswire
Roivant Sciences Launches Datavant to Improve Clinical Trials with Artificial Intelligence
- Datavant aggregates and analyzes biomedical data to lower the time, cost, and risk of drug development 
From PR Newswire
Roivant Strengthens Executive Team with Key Hires and Promotions
- Former GC of Pfizer Allen Waxman joins Roivant 
From PR Newswire
Roivant Sciences Raises $1.1 Billion in Equity Investment Led by SoftBank Vision Fund
-- Investment to fuel creation of new subsidiaries within and beyond biopharmaceutical development, including new technology-enabled 'Vants' 
From PR Newswire
Roivant Sciences Launches Urovant to Develop Innovative Therapies in Urology
- Urovant has licensed vibegron, a Phase 3-ready selective ?3-adrenergic agonist for the treatment of overactive bladder, from Merck 
From PR Newswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.